Quantum BioPharma Ltd. (NASDAQ: QNTM) has signed a Study Start-Up Agreement with Thermo Fisher Scientific's clinical research business to support the Phase 2 clinical trial of Lucid-MS, its investigational drug candidate for progressive multiple sclerosis (MS). The agreement follows the U.S. Food and Drug Administration's clearance of the company's Investigational New Drug application in August 2026 and moves the program toward clinical implementation with a contract research organization experienced in central nervous system and MS studies.
Lucid-MS is designed to protect myelin, the protective coating around nerve fibers, by inhibiting PAD2, an enzyme implicated in myelin damage. This mechanism differs from many existing MS treatments that primarily target the immune system. The randomized, double-blind, placebo-controlled trial will evaluate the candidate's safety, tolerability and efficacy using clinical and radiological measures. Although preclinical research and Phase 1 testing have provided encouraging findings, Lucid-MS remains investigational, and the company has not yet announced enrollment dates or trial sites.
The agreement with Thermo Fisher's clinical research business is a critical operational step for Quantum BioPharma as it seeks to advance a potential first-in-class therapy for progressive MS, a condition with limited treatment options. By targeting myelin protection rather than immune suppression, Lucid-MS could offer a complementary or alternative approach for patients whose disease continues to progress despite existing therapies. For investors, the partnership signals execution on the company's clinical roadmap and provides third-party validation of its trial design.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum is focused on the research and development of its lead compound, Lucid-MS. More information about the company is available at www.QuantumBioPharma.com, and the latest news and updates relating to QNTM can be found in the company's newsroom at https://ibn.fm/QNTM.
The announcement was distributed through InvestorWire, a specialized communications platform focused on advanced wire-grade press release syndication. InvestorWire is one of 75+ brands within the Dynamic Brand Portfolio @ IBN, which delivers access to a vast network of wire solutions, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution via IBN to millions of social media followers, and a full array of tailored corporate communications solutions. For full terms of use and disclaimers applicable to all content provided by InvestorWire, visit https://www.InvestorWire.com/Disclaimer.
